Applied Therapeutics has previously said it hoped to be able to file for accelerated FDA approval based on biomarker data showing that AT-007 was able to reduce levels of galactitol, the main ...

Applied Therapeutics has been sent a warning letter from the FDA over a clinical trial of its rare disease therapy govorestat, which was rejected by the agency last week. The letter – addressed ...

Applied Therapeutics (APLT) (ISIN: US03828A1016)股票专题，提供今日Applied Therapeutics(APLT) (ISIN: US03828A1016)股票最新股价查询，实时市场行情，走势图表，及Applied Therapeutics Inc(APLT) (ISIN: ...

At close: February 25 at 4:00:02 PM EST ...

With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia treatment are ...

Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy (DMD) candidate back on track. The company announced on Monday that the US Food and Drug ...

XORTX Therapeutics (XRTX) has submitted a Type C ... has advanced to the point where a Type C meeting and discussion with the FDA is warranted. The purpose of this meeting is to review the XRx ...

Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's ...